Medindia

X

China Sky One Medical, Inc. Interviewed in The China Perspective

Friday, December 5, 2008 General News J E 4
Advertisement
HARBIN, China, Dec. 5 China Sky One Medical,Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leadingfully integrated pharmaceutical company producing over-the-counter drugs inthe People's Republic of China ("PRC"), announced today that Mr. Yan-Qing Liu,Chairman, CEO and President of China Sky One Medical took part in aninsightful interview in today's issue of The China Perspective.

As a well-known pharmaceutical company in China, China Sky One was honoredto receive an interview from The China Perspective, a leading source of Chinabusiness news, research and analysis that provides insight into the trends,companies and industries that are shaping the Chinese economy. During theinterview, Mr. Yan-Qing Liu spoke about the Company's recent acquisitions, itsR&D capability and the impact of global financial crisis on pharmaceuticalproducers. For more information, please visit The China Perspective's website( http://www.thechinaperspective.com ).

"This is an exciting time in the evolution of the pharmaceutical industryin China, and China Sky One is well positioned to offer insight as a leadingdrug manufacturer and distributor in China," commented Mr. Yan-Qing Liu,Chairman, CEO and President of China Sky One Medical. "We are thrilled to workwith The China Perspective and to share our reflections about the globaleconomic crisis and our expertise in the Chinese pharmaceutical market withthe investment community."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company.The Company engages in the manufacturing, marketing and distribution ofpharmaceutical, medicinal and diagnostic products. Through its wholly-ownedsubsidiaries, Harbin Tian Di Ren Medical Science and Technology Company(''TDR''), Harbin First Bio- Engineering Company Limited ("First"),Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai JinChuang Company Pharmaceutical Company ("Jin Chuang") the Company manufacturesand distributes over-the-counter pharmaceutical products, which make up itsmajor revenue source. For more information, visithttp://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities LitigationReform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should,""project," "plan," "seek," "intend," or "anticipate" or the negative thereofor comparable terminology. Such statements typically involve risks anduncertainties and may include financial projections or information regardingour future plans, objectives or performance. Actual results could differmaterially from the expectations reflected in such forward-looking statementsas a result of a variety of factors, including the risks associated with theeffect of changing economic conditions in The People's Republic of China,variations in cash flow, reliance on collaborative retail partners and on newproduct development, variations in new product development, risks associatedwith rapid technological change, and the potential of introduced or undetectedflaws and defects in products, and other risk factors detailed in reportsfiled with the Securities and Exchange Commission from time to time.For more information, please contact: Company Contact: China Sky One Medical, Inc. Mr. Yubo Hao, CFO Tel: +86-451-5399-4069 Email: china_sky_one@yahoo.cn Investor Relations Contact: CCG Investor Relations Mr. Crocker Coulson, President Tel: +1-646-213-1915 Email: crocker.coulson@ccgir.com Web site: http://www.ccgirasia.com

SOURCE China Sky One Medical, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
DiagnoCure announces fourth quarter and full year ...
S
Cell Therapeutics, Inc. to Offer to Repurchase up ...